

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No. 03-465-D (400.151))

In re A	Application of:)
	McSwiggen et al.) Examiner: TBA
Serial	No.: 10/826,966) Group Art Unit: 1635
Filed:	April 16, 2004) Confirmation No. 2134
For:	RNA Interference Mediated Inhibition of Gene Expression Using Chemically) }
	Modified Nucleic Acid (siNA))

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Attention: Office of Initial Patent Examiner's

Customer Service Center

Dear Sir:

- 1. Attached is a copy of the official filing receipt received from the PTO in the above-referenced application for which issuance of a corrected filing receipt is respectfully requested.
- 2. There is an error with respect to the following data, which is incorrectly entered.

Error In:

Domestic Priority Data as Claimed by Applicants:

PCT/US02/15876 filed

5/20/02

Foreign Applications: PCT/US02/15876, filed 5/20/02

CERTIFICATE OF MAILING (37 C.F.R. 1.8a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the: Commissioner for Patents, Box 1450, Alexandria, VA 22313-1450, on August 9, 2004.

Date: August 9, 2004

U.S.S.N. 10/826,966

Page 2

Attorney Docket No. 03-465-D (400.151)

Correct Data:

Domestic Priority Data as Claimed by Applicants:

PCT/US02/15876 filed

5/17/02

Foreign Applications: PCT/US02/15876, filed 5/17/02

3. The correction is not due to any error by applicant and, accordingly, no fee is due. Applicants submitted the correct priority information on the Application Data Sheet filed with this application. The PTO listed erroneous information in the filing receipt due, it appears, to incorrect data that was in the PTO records. A request for a correction of the data in the PTO database has been submitted, and a copy of that request is attached hereto as Exhibit A.

Respectfully submitted,

Date: August 9, 2004

Registration No. 37,142

FILING RECEIPT

OC000000013253771

CONFIRMATION NO. 2134

020306 MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP 300 S. WACKER DRIVE 32ND FLOOR CHICAGO, IL 60606

Date Mailed: 07/16/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

James McSwiggen, Boulder, CO; Dennis Macejak, Arvada, CO: David Morrisey, Boulder, CO;

Assignment For Published Patent Application

Sirna Therapeutics, Inc., Boulder, CO;

Domestic Priority data as claimed by applicant

This application is a CIP of 10/757,803 01/14/2004 which is a CIP of 10/720,448 11/24/2003. which is a CIP of 10/693,059 10/23/2003 which is a CIP of 10/444,853 05/23/2003 and is a CIP of 10/652,791 08/29/2003 \ which is a CON of 10/422,704 04/24/2003 which is a CON of 10/417,012 04/16/2003 This application 10/826,966 is a CIP of PCT/US03/05346 02/20/2003 and is a CIP of PCT/US03/05028 02/20/2003 and said PCT/US03/05346 02/20/2003 claims benefit of 60/358,580 02/20/2002 and said PCT/US03/05028 02/20/2003 claims benefit of 60/358,580 02/20/2002 and said PCT/US03/05346 02/20/2003 claims benefit of 60/363, 124 03/11/2002 and said PCT/US03/05028 02/20/2003

JUL 19 2004

claims benefit of 60/363,124 03/11/2002 and said PCT/US03/05346 02/20/2003 claims benefit of 60/386,782 06/06/2002 and said PCT/US03/05028 02/20/2003 claims benefit of 60/386,782 06/06/2002 and said PCT/US03/05346 02/20/2003 claims benefit of 60/406,784 08/29/2002 and said PCT/US03/05028 02/20/2003 claims benefit of 60/406,784 08/29/2002 and said PCT/US03/05346 02/20/2003 claims benefit of 60/408,378 09/05/2002 and said PCT/US03/05028 02/20/2003 claims benefit of 60/408,378 09/05/2002 and said PCT/US03/05346 02/20/2003 claims benefit of 60/409,293 09/09/2002 and said PCT/US03/05028 02/20/2003 claims benefit of 60/409.293 09/09/2002 and said PCT/US03/05346 02/20/2003 claims benefit of 60/440,129 01/15/2003 and said PCT/US03/05028 02/20/2003 claims benefit of 60/440,129 01/15/2003 This application 10/826,966 is a CIP of 10/427,160 04/30/2003 and is a CIP of PCT/US02/15876 05/20/2002 * (*)Data provided by applicant is not consistent with PTO records.

Foreign Applications

UNITED STATES OF AMERICA PCT/US03/05346 02/20/2003
UNITED STATES OF AMERICA PCT/US03/05028 02/20/2003
UNITED STATES OF AMERICA PCT/US02/15876 05/20/2002 > 05/07/02

If Required, Foreign Filing License Granted: 07/15/2004

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)

Preliminary Class

514

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).